Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (SNY) with an Equal Weight rating and $56 price target While the valuation is “undemanding” with earnings growth over 2025-28 still similar to peers, concerns over margin and pipeline momentum could see this discount persist as the Sanofi investment case is tied to R&D execution, which “remains a show me story,” the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi to acquire Blueprint Medicines for $129 per share in cash
- Sanofi acquires Blueprint Medicines for $129 per share or $9.1B
- M&A News: Sanofi Expands Cancer Drug Portfolio with $9.1B Blueprint Medicines Acquisition
- Sanofi Strengthens Immunology Pipeline with DR-0201 Acquisition
- Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints